STOCK TITAN

Exelixis Inc - EXEL STOCK NEWS

Welcome to our dedicated news page for Exelixis (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exelixis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exelixis's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences
-
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
earnings
Exelixis Inc

Nasdaq:EXEL

EXEL Rankings

EXEL Stock Data

7.23B
255.76M
2.34%
87.45%
2.92%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Alameda

About EXEL

exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.